Panel Rules Pfizer Can't Get New MDL Over Cancer Drug IP
The Judicial Panel on Multidistrict Litigation Friday declined to consolidate eight more abbreviated new drug application suits brought by Pfizer accusing generic-drug makers of infringing a breast cancer treatment patent, finding...To view the full article, register now.
Already a subscriber? Click here to view full article